The use of desloratadine in monotherapy and combination therapies in the treatment of allergic rhinitis Review article
Article Sidebar
Published:
Mar 31, 2016
Keywords:
desloratadine, mometasone furoate, allergic rhinitis
Main Article Content
Abstract
Antihistamines are the most popular drugs used in allergic rhinitis. Desloratadine is a modern second-generation drug that had no effect on the central nervous and does not change the weight. Effectively reduces the symptoms of allergic rhinitis in adults and children. It is characterized by a high safety level. Additive therapeutic effect of desloratadine with nasal corticosteroids is promising, but requires further research.
Article Details
How to Cite
Sokołowski, R. (2016). The use of desloratadine in monotherapy and combination therapies in the treatment of allergic rhinitis. Medycyna Faktow (J EBM), 9(1(30), 36-40. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2267
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Benninger M.S., Benninger R.M.: The impact of allergic rhinitis on sexual activity, sleep, and fatigue. Allergy Asthma Proc. 2009; 30(4): 358-365.
2. Blaiss M.S.: Pediatric allergic rhinitis: physical and mental complications. Allergy Asthma Proc. 2008; 29(1): 1-6.
3. Bloom M., Staudinger H., Herron J.: Safety of desloratadine syrup in children. Curr. Med. Res. Opin. 2004; 20(12): 1959-1965.
4. Bousquet J., Khaltaev N., Cruz A.A. et al.: Allergic Rhinitis and its impact of Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63(supl. 86): 8-160.
5. Cavanah D.K., Casale T.B.: Histamine. W: Kaliner M.A., Metcalfe D.D. (red.): The Mast Cell in Health and Disease. Marcel Dekker, Inc. 1993: 321-342, seria: Lung Biology in Health and Disease.
6. Chervinsky P., Georgitis J., Banov C. et al.: Once daily loratadine versus astemizole once daily. Ann. Allergy 1994; 73: 109-113.
7. Anolik R.; Mometasone Furoate Nasal Spray With Loratadine Study Group: Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 2008; 100(3): 264-271.
8. Dinges D.F., Pack F., Williams K. et al.: Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during week of sleep restricted to 4-5 hours per night. Sleep. 1997; 20: 267-277.
9. Gelardi M., Russo C., Fiorella M.L. et al.: When allergic rhinitis is not only allergic. Am. J. Rhinol. Allergy 2009; 23: 312-315.
10. Genovese A., Patella V., De Crescenzo G. et al.: Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin. Exp. Allergy 1997; 27(5): 559-567.
11. Gupta S., Khalilieh S., Kantesaria B. et al.: Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br. J. Clin. Pharmacol. 2007; 63(5): 534-540.
12. Holmberg K., Tonnel A.B., Dreyfus I. et al.: Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis. Allergy 2009; 64(11): 1663-1670.
13. Kaditis A.G., Finder J., Alexopoulos E.L. et al.: Sleep-disordered breathing in 3,680 Greek children. Pediatr. Pulmonol. 2004; 37: 499-509.
14. Kirmaz C., Aydemir O., Bayrak P. et al.: Sexual dysfunction in patients with allergic rhinoconjunctivitis. Ann. Allergy Asthma Immunol. 2005; 95(6): 525-529.
15. Kmiecik B., Skotny A., Batycka M. et al.: Wpływ stresu oksydacyjnego na procesy regeneracji tkankowej. Polim. Med. 2013; 43(3): 191-197.
16. Kripke D.F., Simons R.N., Garfinkel L., Hammond E.C.: Short and long sleep and sleeping pills. Is increased mortality associated? Arch. Gen. Psychiatr. 1979; 36(1): 103-116.
17. Léger D., Annesi-Maesano I., Carat F. et al.: Allergic rhinitis and its consequences on quality of sleep: An unexplored area. Arch. Intern. Med. 2006; 166(16): 1744-1748 .
18. Lieberman P.: The basics of histamine biology. Ann. Allergy Asthma Immunol. 2011; 106(supl. 2): S2-5.
19. Mir E., Panjabi C., Shah A.: Impact of allergic rhinitis in school going children. Asia Pac. Allergy. 2012; 2(2): 93-100.
20. Mullol J., de Borja Callejas F., Martínez-Antón M.A. et al.: Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells. Respir. Research 2011; 12(1): 23.
21. Mygindin D.: Epidemiology of allergic rhinitis. Pediatr. Allergy Immunol. 1996; 7(supl. 9): 57-62.
22. Ng D.K., Chan C.H., Kwok K.L., Cheung J.M.: Allergic rhinitis as a risk factor for habitual snoring in children. Chest. 2005; 127: 2285-2286.
23. Onrust S.V., Lamb H.M.: Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 1998; 56(4): 725-745.
24. Orthen-Gambill N.: Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats. Pharmacol. Biochem. Behav. 1988; 31(1): 81-86.
25. Kakumanu S., Glass C., Craig T.: Poor sleep and daytime somnolence in allergic rhinitis: significance of nasal congestion. Am. J. Respir. Med. 2002; 1(3): 195-200.
26. Rolf H., Kjetil H., Olof B. et al.: Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomized controlled study [ISRCTN23032971]. Clin. Mol. Allergy 2005; 3: 3.
27. Sadowska-Woda I., Bieszczad-Bedrejczuk E., Rachel M.: Influence of desloratadine on selected oxidative stress markers in patients between 3 and 10 years of age with allergic perennial rhinitis. Eur. J. Pharmacol. 2010; 640(1-3): 197-201.
28. Samoliński B., Sybilski A.J., Raciborski F. et al.: Prevalance of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol. Pol. 2009; 63(4): 324-330.
29. Schroeder J.T., Schleimer R.P., Lichtenstein L.M. et al.: Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin. Exp. Allergy [in press].
30. Spicak V., Dab I., Hulhoven R. et al.: Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. Clin. Pharmacol. Ther. 1997; 61: 325-330.
31. Tassinari P., Suárez N.R., Centeno J. et al.: Desloratadine therapy improves allergic rhinitis symptoms in latin american children aged 6 to 12 years. World Allergy Organ. J. 2009; 2(4): 42-48.
32. Tamer M.H. Adham: Treatment of Allergic Rhinitis With Desloratadine: Results of a Multinational Observational Study in the Middle East Gulf Region. World Allergy Organ. J. 2011; 4(8): 130-134.
33. Valk P.J., Van Roon D.B., Simons R.M., Rikken G.: Desloratadine shows no effect on performance during 6 h at 8,000 ft simulated cabin altitude. Aviat. Space Environ. Med. 2004; 75(5): 433-438.
34. Vaziri P., Dang K., Anderson G.H.: Evidence for histamine involvement in the effect of histidine loads on food and water intake in rats. J. Nutr. 1997; 127(8): 1519-1526.
35. Yuksel H., Sogut A., Yilmaz H. et al.: Sleep actigraphy evidence of improved sleep after treatment of allergic rhinitis. Ann. Allergy Asthma Immunol. 2009; 103(4): 290-294.
2. Blaiss M.S.: Pediatric allergic rhinitis: physical and mental complications. Allergy Asthma Proc. 2008; 29(1): 1-6.
3. Bloom M., Staudinger H., Herron J.: Safety of desloratadine syrup in children. Curr. Med. Res. Opin. 2004; 20(12): 1959-1965.
4. Bousquet J., Khaltaev N., Cruz A.A. et al.: Allergic Rhinitis and its impact of Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63(supl. 86): 8-160.
5. Cavanah D.K., Casale T.B.: Histamine. W: Kaliner M.A., Metcalfe D.D. (red.): The Mast Cell in Health and Disease. Marcel Dekker, Inc. 1993: 321-342, seria: Lung Biology in Health and Disease.
6. Chervinsky P., Georgitis J., Banov C. et al.: Once daily loratadine versus astemizole once daily. Ann. Allergy 1994; 73: 109-113.
7. Anolik R.; Mometasone Furoate Nasal Spray With Loratadine Study Group: Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 2008; 100(3): 264-271.
8. Dinges D.F., Pack F., Williams K. et al.: Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during week of sleep restricted to 4-5 hours per night. Sleep. 1997; 20: 267-277.
9. Gelardi M., Russo C., Fiorella M.L. et al.: When allergic rhinitis is not only allergic. Am. J. Rhinol. Allergy 2009; 23: 312-315.
10. Genovese A., Patella V., De Crescenzo G. et al.: Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin. Exp. Allergy 1997; 27(5): 559-567.
11. Gupta S., Khalilieh S., Kantesaria B. et al.: Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br. J. Clin. Pharmacol. 2007; 63(5): 534-540.
12. Holmberg K., Tonnel A.B., Dreyfus I. et al.: Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis. Allergy 2009; 64(11): 1663-1670.
13. Kaditis A.G., Finder J., Alexopoulos E.L. et al.: Sleep-disordered breathing in 3,680 Greek children. Pediatr. Pulmonol. 2004; 37: 499-509.
14. Kirmaz C., Aydemir O., Bayrak P. et al.: Sexual dysfunction in patients with allergic rhinoconjunctivitis. Ann. Allergy Asthma Immunol. 2005; 95(6): 525-529.
15. Kmiecik B., Skotny A., Batycka M. et al.: Wpływ stresu oksydacyjnego na procesy regeneracji tkankowej. Polim. Med. 2013; 43(3): 191-197.
16. Kripke D.F., Simons R.N., Garfinkel L., Hammond E.C.: Short and long sleep and sleeping pills. Is increased mortality associated? Arch. Gen. Psychiatr. 1979; 36(1): 103-116.
17. Léger D., Annesi-Maesano I., Carat F. et al.: Allergic rhinitis and its consequences on quality of sleep: An unexplored area. Arch. Intern. Med. 2006; 166(16): 1744-1748 .
18. Lieberman P.: The basics of histamine biology. Ann. Allergy Asthma Immunol. 2011; 106(supl. 2): S2-5.
19. Mir E., Panjabi C., Shah A.: Impact of allergic rhinitis in school going children. Asia Pac. Allergy. 2012; 2(2): 93-100.
20. Mullol J., de Borja Callejas F., Martínez-Antón M.A. et al.: Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells. Respir. Research 2011; 12(1): 23.
21. Mygindin D.: Epidemiology of allergic rhinitis. Pediatr. Allergy Immunol. 1996; 7(supl. 9): 57-62.
22. Ng D.K., Chan C.H., Kwok K.L., Cheung J.M.: Allergic rhinitis as a risk factor for habitual snoring in children. Chest. 2005; 127: 2285-2286.
23. Onrust S.V., Lamb H.M.: Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 1998; 56(4): 725-745.
24. Orthen-Gambill N.: Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats. Pharmacol. Biochem. Behav. 1988; 31(1): 81-86.
25. Kakumanu S., Glass C., Craig T.: Poor sleep and daytime somnolence in allergic rhinitis: significance of nasal congestion. Am. J. Respir. Med. 2002; 1(3): 195-200.
26. Rolf H., Kjetil H., Olof B. et al.: Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomized controlled study [ISRCTN23032971]. Clin. Mol. Allergy 2005; 3: 3.
27. Sadowska-Woda I., Bieszczad-Bedrejczuk E., Rachel M.: Influence of desloratadine on selected oxidative stress markers in patients between 3 and 10 years of age with allergic perennial rhinitis. Eur. J. Pharmacol. 2010; 640(1-3): 197-201.
28. Samoliński B., Sybilski A.J., Raciborski F. et al.: Prevalance of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol. Pol. 2009; 63(4): 324-330.
29. Schroeder J.T., Schleimer R.P., Lichtenstein L.M. et al.: Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin. Exp. Allergy [in press].
30. Spicak V., Dab I., Hulhoven R. et al.: Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. Clin. Pharmacol. Ther. 1997; 61: 325-330.
31. Tassinari P., Suárez N.R., Centeno J. et al.: Desloratadine therapy improves allergic rhinitis symptoms in latin american children aged 6 to 12 years. World Allergy Organ. J. 2009; 2(4): 42-48.
32. Tamer M.H. Adham: Treatment of Allergic Rhinitis With Desloratadine: Results of a Multinational Observational Study in the Middle East Gulf Region. World Allergy Organ. J. 2011; 4(8): 130-134.
33. Valk P.J., Van Roon D.B., Simons R.M., Rikken G.: Desloratadine shows no effect on performance during 6 h at 8,000 ft simulated cabin altitude. Aviat. Space Environ. Med. 2004; 75(5): 433-438.
34. Vaziri P., Dang K., Anderson G.H.: Evidence for histamine involvement in the effect of histidine loads on food and water intake in rats. J. Nutr. 1997; 127(8): 1519-1526.
35. Yuksel H., Sogut A., Yilmaz H. et al.: Sleep actigraphy evidence of improved sleep after treatment of allergic rhinitis. Ann. Allergy Asthma Immunol. 2009; 103(4): 290-294.